Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520713 · ClinicalTrials.gov registry record
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
A clinical trial of Pediatric Solid Tumor, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 825
- Enrollment target
- 12
- Study locations
NCT02520713 is a study of Pediatric Solid Tumor that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 825 participants, below the 1,050-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (21% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT02520713, a study of Pediatric Solid Tumor, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 825 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.
Conditions Studied
Interventions
- GENETIC Genetic testing and GAIN report
Study Locations (12)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- University of Chicago Comer Children's Hospital - Chicago
New York
- Columbia University Medical Center - New York
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02520713
The ClinicalTrials.gov registry entry for NCT02520713 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 825 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,050-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (21% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Genetic testing and GAIN report is the first listed.
NCT02520713 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02520713 about?
NCT02520713 is a clinical study titled "The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study". This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may ...
What is the current status of trial NCT02520713?
This trial is currently active not recruiting. The enrollment target is 825 participants. The study started on 2015-10. Estimated completion is 2026-10.
What conditions does trial NCT02520713 study?
This clinical trial studies the following conditions: Pediatric Solid Tumor.
What interventions are being tested in trial NCT02520713?
The interventions under investigation include: Genetic testing and GAIN report (GENETIC).
Who is sponsoring clinical trial NCT02520713?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02520713 being conducted?
This trial has 12 study locations across California, Colorado, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
RECRUITING · Phase 1
-
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
RECRUITING
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.